Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Salamanca
Clinical trial register · Spain

Clinical Trials in Salamanca, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5909 matching records held by the registry are in this view. Synced 13 Nov 2026, 03:19 UTC
5909
Studies in scope
all four open statuses
3100
Recruiting now
open to new participants
1129
Lead sponsors
across recruiting studies
Top sites
Barcelona 3245 Madrid 3071 Valencia 1206 Seville 1059 Málaga 762
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC29 University of Salamanca20 AstraZeneca16 Novartis Pharmaceuticals15 Instituto de Investigación Biomédica de Salamanca13 Bristol-Myers Squibb9 Celgene9 Merck Sharp & Dohme LLC9 Takeda9 Regeneron Pharmaceuticals7 GlaxoSmithKline7 PETHEMA Foundation7 AbbVie7 Hoffmann-La Roche7 Incyte Corporation6 BeOne Medicines5 Abbott Medical Devices5 Eli Lilly and Company5 Kite, A Gilead Company5 Sanofi4 Medtronic4 Genmab4 Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León4 European Organisation for Research and Treatment of Cancer - EORTC4 Fundación EPIC4 Show all 142
Site location
Barcelona3245 Madrid3071 Valencia1206 Seville1059 Málaga762 Pamplona612 Badalona565 A Coruña490 Córdoba449 L'Hospitalet de Llobregat448 Santander405 Santiago de Compostela390 Salamanca363 Granada321 Alicante275 Majadahonda274 Zaragoza261 Oviedo235 Murcia234 Girona222 Las Palmas de Gran Canaria207 Sabadell183 Palma de Mallorca174 Bilbao155 Pozuelo de Alarcón154 Show all 463
All 463 locations
Target enrolment
to

Trials with a site in Salamanca

363 of 5909 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Jaén, Málaga, Palma de Mallorca, Salamanca, Barcelona, L'Hospitalet de Llobregat, Valencia, A Coruña
2027-11-23
Not yet open
Shenzhen Lifevalve Medical Scientific Co., Ltd.
Not applicable
15
Barcelona, Salamanca, Vigo
2027-03-01
Not yet open
Neurofeedback for Episodic Migraine
NCT07661888Episodic Migraine
University of Salamanca
Not applicable
66
Salamanca
2026-11-15
Not yet open
Novo Nordisk A/S
Phase 3
1,060
Barcelona, Girona, L'Hospitalet de Llobregat, Monzón, Salamanca, Seville
2026-11-10
Not yet open
Eli Lilly and Company
Phase 2
330
Alcorcón, Barcelona, Madrid, Salamanca, Valdemoro, Vigo, Zamora
2026-11
Not yet open
PETHEMA Foundation
Phase 2
30
Badalona, Barcelona, Madrid, Málaga, Salamanca, San Sebastián, Santander, Seville
2026-10-30
Recruiting
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
NCT07709000Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic Malignancies
DrugsAvtozma·Tyenne·Siltuximab·MK-1045
Merck Sharp & Dohme LLC
Phase 2
60
Salamanca
2026-10-14
Recruiting
AstraZeneca
Phase 3
750
Badalona, Barcelona, El Palmar, Madrid, Salamanca, Santander, Seville
2026-09-24
Recruiting
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Phase 1/2
10
Badalona, Santiago de Compostela, Pamplona, León, Madrid, Murcia, Salamanca, Seville
2026-09-23
Recruiting
Takeda
Phase 3
324
Santiago de Compostela, Badalona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Málaga, Barcelona, Madrid, Salamanca
2026-09-10
Not yet open
Polyphenol Intake, Mediterranean Diet Adherence, and Oxidative Stress in Pregnancy
NCT07656532Pregnancy, Gestational Diabetes Mellitus (GDM), Preeclampsia, Hypertension, Pregnancy-Induced
University of Salamanca
Not applicable
60
Salamanca
2026-09-01
Not yet open
University of Salamanca
Not applicable
40
Salamanca
2026-09-01
Not yet open
Philippe ROUSSELOT
Phase 2
93
Barcelona, Madrid, Málaga, Murcia, Salamanca, San Sebastián, Santander, Seville
2026-09-01
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Barcelona, Jaén, Madrid, Murcia, Salamanca, Sanlúcar de Barrameda (Cádiz), Seville, Valencia
2026-08-24
Recruiting
Eli Lilly and Company
Phase 3
1,000
Barcelona, Centelles, Madrid, Oviedo, Salamanca, Seville, Zamora
2026-08-14
Recruiting
Spanish Prospective Registry of Hydra THV for Transcatheter Aortic Valve Implantation
NCT07566624Severe Aortic Valve Stenosis, Valvular Heart Disease, Aortic Valve Stenosis
Fundación EPIC
Observational
100
Aravaca, Barcelona, Fuencarral-El Pardo, L'Hospitalet de Llobregat, Salamanca, Santiago de Compostela, Seville, Toledo
2026-07-07
Not yet open
ORLINT & ORLEXT: Orthosis for Knee
NCT07333911Knee Brace, Knee
University of Salamanca
Not applicable
4
Salamanca
2026-07-01
Active, closed
University of Salamanca
Not applicable
50
Salamanca
2026-07-01
Recruiting
University of Salamanca
Not applicable
40
Salamanca
2026-07-01
Not yet open
EQUISOCK: New Antiequine
NCT07333768Ankle (Ligaments); Instability (Old Injury), Ankle Equinus, Ankle Dorsiflexion
University of Salamanca
Not applicable
4
Salamanca
2026-07-01
Recruiting
AstraZeneca
Phase 3
750
Badalona, Barcelona, Madrid, Pamplona, Salamanca, Seville, Valencia
2026-06-26
Recruiting
Hoffmann-La Roche
Phase 3
380
Badalona, Marbella, Pamplona, Barcelona, Madrid, Salamanca
2026-06-23
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
960
Badalona, Málaga, Barcelona, Madrid, Salamanca
2026-06-22
Recruiting
GlaxoSmithKline
Phase 1/2
49
Barcelona, Madrid, Salamanca, Valencia
2026-06-19
Recruiting
OPTION-EMEA Clinical Trial
NCT07349121Atrial Fibrillation (AF), Stroke Prevention in Patients With Atrial Fibrillation, Left Atrial Appendage Closure, Pulsed Field Ablation
Boston Scientific Corporation
Not applicable
500
Salamanca, Valencia, Vigo
2026-06-18
Active, closed
AstraZeneca
Phase 2
326
Barcelona, Jaén, L'Hospitalet de Llobregat, Majadahonda, Málaga, Pamplona, Salamanca, Valencia
2026-06-11
Recruiting
Regeneron Pharmaceuticals
Phase 3
35
Bilbao, Barcelona, Cáceres, Murcia, Salamanca
2026-06-11
Recruiting
Instituto de Investigación Biomédica de Salamanca
Observational
350
Barcelona, Salamanca, Seville
2026-06-09
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Barcelona, Cáceres, Córdoba, Jerez de la Frontera, Madrid, Pamplona, Salamanca, Santander
2026-05-31
Active, closed
Kite, A Gilead Company
Phase 3
550
Barcelona, Madrid, Pamplona, Salamanca
2026-05-22
Recruiting
Takeda
Phase 3
300
L'Hospitalet de Llobregat, Seville, Barcelona, Madrid, Málaga, Salamanca, Valencia
2026-05-21
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
340
Badalona, Pamplona, Oviedo, Valencia, Madrid, Salamanca
2026-05-18
Recruiting
Regeneron Pharmaceuticals
Phase 2
99
Barcelona, Marbella, Madrid, Salamanca, Toledo
2026-05-06
Recruiting
Eli Lilly and Company
Phase 2
531
Barcelona, Centelles, Granada, Madrid, Marbella, Salamanca, Santiago de Compostela
2026-05-06
Not yet open
University of Salamanca
Not applicable
75
Salamanca
2026-05-01
Not yet open
REACTION-VAD Trial: Remote Exercise Training Via Telemedicine in Patients With Long-Term Ventricular Assist Devices
NCT07611188Heart Failure, Advanced Heart Failure, Left Ventricular Assist Device, LVAD
Puerta de Hierro University Hospital
Not applicable
78
Seville, Salamanca, Barcelona, A Coruña, Santiago de Compostela, Madrid, Majadahonda
2026-05
Recruiting
Eli Lilly and Company
Phase 2
342
Barcelona, Centelles, Granada, Madrid, Marbella, Salamanca, Santiago de Compostela
2026-04-29
Recruiting
GlaxoSmithKline
Phase 2
200
Jerez de la Frontera, Badalona, Córdoba, Gijón, Madrid, Málaga, Salamanca, Vitoria-Gasteiz
2026-04-15
Recruiting
Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas
Phase 2
30
Barcelona, Jerez de la Frontera, Madrid, Murcia, Salamanca, Valencia
2026-04-15
Recruiting
Instituto de Investigación Biomédica de Salamanca
Observational
300
Salamanca
2026-04-01
Recruiting
SymBio Pharmaceuticals
Phase 3
180
Barcelona, Madrid, Pamplona, Salamanca
2026-03-17
Active, closed
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398Pulmonary Hypertension Associated With HFpEF
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
540
Barcelona, Lugo, Madrid, Marbella, Málaga, Pamplona, Salamanca, Seville
2026-03-03
Recruiting
Instituto de Investigación Marqués de Valdecilla
Not applicable
220
Burgos, Málaga, Salamanca, Santander
2026-03-01
Recruiting
Instituto de Investigación Biomédica de Salamanca
Phase 3
300
Salamanca, Almería, Barakaldo, Girona, Las Palmas de Gran Canaria, Madrid, Murcia, Santander
2026-03-01
Recruiting
Instituto de Investigación Biomédica de Salamanca
Phase 4
122
Salamanca, Zamora
2026-02-26
Recruiting
AstraZeneca
Phase 3
508
Barcelona, Madrid, Pamplona, Salamanca, Santander, Valencia
2026-02-23
Recruiting
C4 Therapeutics, Inc.
Phase 2
100
Barcelona, El Palmar, Gijón, León, Madrid, Pamplona, Salamanca
2026-02-18
Recruiting
Boehringer Ingelheim
Phase 3
1,325
A Coruña, Alicante, Barakaldo, Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Salamanca
2026-02-17
Recruiting
Elion Therapeutics, Inc.
Phase 2
60
Barcelona, Madrid, Majadahonda, Salamanca
2026-02-13
Recruiting
Eli Lilly and Company
Phase 3
1,000
Barcelona, Madrid, Oviedo, Salamanca, Zamora
2026-02-09
Recruiting
Instituto de Investigación Biomédica de Salamanca
Observational
400
Salamanca
2026-02-09
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Badalona, Barcelona, Granada, Madrid, Pozuelo de Alarcón, Salamanca, Usansolo, Valencia
2026-02-04
Not yet open
Preparation for Sports Retirement: Study Protocol
NCT07303504Sport Retirement, Psychoeducation, Retirement, Adaptation
University of Salamanca
Not applicable
26
Salamanca
2026-02-01
Recruiting
ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure
NCT07484009Acute Heart Failure (AHF), Heart Failure (for Example, Fluid Overload), Heart Failure Hospitalization
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Not applicable
1,014
Madrid, Barcelona, Córdoba, Girona, Málaga, Murcia, Salamanca, Sant Joan Despí
2026-01-29
Recruiting
Takeda
Phase 3
183
Madrid, Marbella, Palma de Mallorca, Salamanca, Valencia
2026-01-14
Recruiting
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Observational
1,500
Leganés, Barcelona, Lleida, Madrid, Murcia, Pamplona, Salamanca, Santiago de Compostela
2026-01-13
Recruiting
Universidad Pontificia de Salamanca
Not applicable
40
Salamanca
2026-01-10
Recruiting
Exercise During Hemodialysis: Impact on Sarcopenia and Sleep Quality
NCT07447375Sarcopenia, Renal Insufficiency, Chronic
University of Salamanca
Not applicable
58
Salamanca
2026-01-02
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Santiago de Compostela, Barcelona, Madrid, Pamplona, Badalona, Elche, Málaga, Salamanca
2025-12-31
Recruiting
Grupo Español de Investigación en Neurooncología
Phase 2
56
Palma de Mallorca, Barcelona, Barakaldo, Granada, Madrid, Vigo, Salamanca, Seville
2025-12-19
Active, closed
WATCHMAN FLX Pro European Registry
NCT07262255Non-valvular Atrial Fibrillation (AF), Left Atrial Appendage Closure
Boston Scientific Corporation
Observational
189
León, Pamplona, Pontevedra, Salamanca
2025-12-17
Recruiting
European Myeloma Network B.V.
Phase 2
150
Barcelona, Las Palmas, Murcia, Salamanca
2025-12-12
Recruiting
Universidad Pontificia de Salamanca
Not applicable
40
Salamanca
2025-12-09
Recruiting
Bristol-Myers Squibb
Phase 3
650
Getxo, Elche (alicante), Madrid, Málaga, Pamplona, Salamanca, Seville, Terrassa
2025-12-02
Recruiting
University of Salamanca
Not applicable
36
Salamanca
2025-11-21
Recruiting
Hospital General Universitario Gregorio Marañon
Phase 3
103
Barcelona, Madrid, Salamanca, Zamora
2025-11-20
Recruiting
iOnctura
Phase 1/2
26
Barcelona, Madrid, Salamanca
2025-11-17
Recruiting
AstraZeneca
Phase 1/2
83
Badalona, Barcelona, Salamanca, Santander, Valencia
2025-11-12
Recruiting
AstraZeneca
Phase 1
72
Barcelona, Madrid, Pamplona, Salamanca, Valencia
2025-11-03
Recruiting
Novo Nordisk A/S
Phase 1
30
Barcelona, Madrid, Málaga, Salamanca, Valencia
2025-10-23
Recruiting
Fundación EPIC
Not applicable
200
Alicante, Barcelona, Córdoba, Fuencarral-El Pardo, Lugo, Madrid, Salamanca, Seville
2025-10-23
Recruiting
ACURES: Acoustic and Respiratory Parameters for Dysarthria Assessment
NCT07435155Dysarthria, Acquired Brain Injury
University of Salamanca
Observational
100
Salamanca
2025-10-15
Recruiting
Celgene
Phase 1/2
62
Santander, Salamanca
2025-10-07
Recruiting
Janssen Research & Development, LLC
Phase 2
60
Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander, Seville
2025-10-03
Recruiting
Novartis Pharmaceuticals
Phase 3
300
Santiago Compostela, Huelva, El Palmar, Las Palmas GC, Madrid, Salamanca, Seville, Valencia
2025-10-03
Recruiting
University of Salamanca
Not applicable
100
Salamanca
2025-10-01
Recruiting
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2
50
Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, El Palmar, Marbella, Pamplona, Salamanca
2025-09-30
Recruiting
Kura Oncology, Inc.
Phase 3
1,300
Seville, Zaragoza, Burgos, Salamanca, Albacete, Madrid, Oviedo, Valencia
2025-09-26
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
Badalona, Barcelona, Las Palmas de Gran Canaria, Alcorcón, Málaga, Salamanca, Seville, Madrid
2025-09-22
Recruiting
Instituto de Investigación Biomédica de Salamanca
Not applicable
95
Madrid, Salamanca, Valencia
2025-09-15
Recruiting
Effects of Treadmill-Based Gait Training in Patients With Stroke
NCT07127861Gait, Thermography, Walking Speed, Mesh id D000072797, Endurance
University of Salamanca
Not applicable
24
Salamanca
2025-09-14
Recruiting
Hoffmann-La Roche
Phase 2
120
Barcelona, Madrid, Salamanca, Seville, Valencia
2025-09-09
Recruiting
AbbVie
Phase 2
140
Seville, Madrid, Salamanca
2025-09-02
Not yet open
University of Salamanca
Observational
150
Salamanca
2025-09-01
Not yet open
Federation Francophone de Cancerologie Digestive
Phase 2
300
Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Oviedo, Pamplona, Salamanca, San Carlos
2025-08-31
Recruiting
Takeda
Phase 3
150
Alcorcón, Madrid, Burgos, Salamanca, Seville
2025-08-14
Recruiting
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2
80
Seville, Zaragoza, Palma de Mallorca, Burgos, Salamanca, Badalona, Barcelona, Cáceres
2025-08-04
Recruiting
Instituto de Investigación Biomédica de Salamanca
Observational
30
Salamanca
2025-07-17
Recruiting
Evaluation of a Diagnostic Software for Coronary Artery Disease Using Retrospective CCTA Data (CODEX-1 Study)
NCT06977295Coronary Artery Disease, Atherosclerosis, Myocardial Ischemia
Instituto de Investigación Biomédica de Salamanca
Observational
1,000
Salamanca
2025-07-14
Recruiting
Bristol-Myers Squibb
Phase 3
426
Getxo, Elche (alicante), Madrid, Málaga, Pamplona, Salamanca, Seville, Terrassa
2025-07-10
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Paraplatin
Merck Sharp & Dohme LLC
Phase 3
2,400
L'Hospitalet de Llobregat, Bilbao, Salamanca, Jaén, Santiago de Compostela, Pozuelo de Alarcón, Valencia, Barcelona
2025-06-30
Recruiting
PETHEMA Foundation
Phase 2
30
Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander, Santiago de Compostela, Seville
2025-06-30
Recruiting
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
NCT06409936CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia, BCR/ABL-Positive, Chronic Myeloid Leukemia
DrugsAsciminib·Nilotinib
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2
160
Barcelona, Bilbao, Girona, Granada, Las Palmas de Gran Canaria, Madrid, Murcia, Salamanca
2025-06-26
By invitation
Effect of an App-based Intervention on Air Pollution in COPD Patients
NCT07074093COPD (Chronic Obstructive Pulmonary Disease)
Fundacion para la Investigacion y Formacion en Ciencias de la Salud
Not applicable
150
Salamanca
2025-06-16
Recruiting
Orbital Atherectomy vs Intravascular Lithotripsy for the Treatment of Calcified Coronary Nodules (ORBIT-SHOCK).
NCT06736665Coronary Arterial Disease (CAD), Coronary Calcification, Coronary Calcified Nodules, Orbital Atherectomy
Spanish Society of Cardiology
Not applicable
50
Alicante, Lugo, Madrid, Salamanca, Valladolid, Córdoba
2025-06-12
Recruiting
BeOne Medicines
Phase 3
630
Barcelona, LHospitalet de Llobregat, Madrid, Marbella, Salamanca, Santander, Seville
2025-06-11
Recruiting
GlaxoSmithKline
Phase 2
80
Barcelona, Madrid, Málaga, Ourense, PamplonaNavarra, Salamanca, Valencia
2025-06-05
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
L'Hospitalet de Llobregat, Oviedo, Barcelona, Madrid, Salamanca
2025-05-30
Recruiting
Swedish Orphan Biovitrum
Phase 2
156
Barcelona, L'Hospitalet de Llobregat, Salamanca
2025-05-28
Active, closed
Swedish Orphan Biovitrum
Phase 4
252
Salamanca, A Coruña, Barcelona, Málaga, Palma de Mallorca, Zaragoza
2025-05-21
Recruiting
SecuraBio
Phase 3
124
Barcelona, Madrid, Salamanca, Seville
2025-05-19
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
DrugAcoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3
587
A Coruña, Barcelona, Huelva, Majadahonda, Palma de Mallorca, Salamanca
2025-05-12
Recruiting
Takeda
Phase 3
225
Salamanca, Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia
2025-05-06
Recruiting
University of Salamanca
Not applicable
198
Salamanca
2025-05-01
Recruiting
Observational Study of Platelet Dysfunction Assessed by Thromboelastography in Cardiovascular Surgery (DISPLATEG)
NCT06961175Blood Platelet Disorders, Cardiac Surgery, Postoperative Bleeding
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Observational
180
Salamanca
2025-05-01
Not yet open
Fundacion Clinic per a la Recerca Biomédica
Phase 2
25
Santander, Madrid, Murcia, Pamplona, Salamanca, Barcelona
2025-04
Recruiting
Universidad Católica de Ávila
Observational
20
Salamanca
2025-03-31
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Santiago de Compostela, Palma, Badalona, Pamplona, Granada, Salamanca
2025-03-12
Recruiting
Alleviant ALLAY-HFrEF Study
NCT06812533Heart Failure
Alleviant Medical, Inc.
Not applicable
350
A Coruña, Barcelona, Madrid, Salamanca, Valencia
2025-03-10
Active, closed
An Ophthalmic Safety Study in Patients With Breast Cancer
NCT06767462Ophthalmic Safety in Patients With Breast Cancer
AstraZeneca
Observational
160
Badalona, Barcelona, Girona, L'Hospitalet de Llobregat, Leganés, Madrid, Majadahonda, Salamanca
2025-03-05
Recruiting
Takeda
Phase 3
171
Alcorcón, Madrid, Salamanca, Seville
2025-02-27
Not yet open
Enrique Rodilla
Not applicable
1,246
Sagunto (valencia), Madrid, Salamanca
2025-02-01
Recruiting
Universidad Católica de Ávila
Not applicable
20
Salamanca
2025-01-31
Recruiting
Incyte Corporation
Phase 3
240
Barcelona, Donostia / San Sebastian, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda, Salamanca, Seville
2025-01-21
Recruiting
Loxo Oncology, Inc.
Phase 2
249
Barcelona, L'Hospitalet Del Llobregat, Madrid, Majadahonda, Marbella, Oviedo, Salamanca, Santander
2025-01-03
Recruiting
Instituto de Investigación Marqués de Valdecilla
Phase 4
75
Barakaldo, Jerez de la Frontera, Madrid, Salamanca, Santander, Seville, Valladolid
2024-12-31
Not yet open
Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant
NCT05982275Multiple Myeloma, Allogeneic Stem Cell Transplantation
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase 1/2
25
Santander, Barcelona, Salamanca, Seville, Valencia
2024-12-30
By invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
NCT06788509Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
DrugsJNJ-75348780·JNJ-87801493·JNJ-80948543·Ibrutinib
Janssen Research & Development, LLC
Phase 1
120
Barcelona, Madrid, Pamplona, Salamanca
2024-12-30
Active, closed
Janssen Research & Development, LLC
Phase 1
17
Badalona, Barcelona, Madrid, Pamplona, Salamanca
2024-12-19
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Málaga, Salamanca
2024-12-17
Recruiting
GlaxoSmithKline
Phase 3
520
Badalona, Barcelona, Gijón, Madrid, Málaga, Murcia, Salamanca, Santander
2024-12-16
Recruiting
Ryvu Therapeutics SA
Phase 2
178
Barcelona, Madrid, Murcia, Pamplona, Salamanca, Seville, Zaragoza
2024-12-05
Recruiting
Janssen Research & Development, LLC
Phase 1
276
Barcelona, Salamanca
2024-12-04
Recruiting
Institut de Recherches Internationales Servier
Phase 3
48
Badalona, Barcelona, Madrid, Pamplona, Salamanca, Seville, Valencia
2024-12-03
Active, closed
AstraZeneca
Phase 3
181
Barcelona, Cadiz, Madrid, Salamanca, Santiago de Compostela
2024-12-03
Recruiting
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2
45
A Coruña, Palma de Mallorca, Santander, Salamanca, Barcelona, L'Hospitalet de Llobregat, San Sebastián, Las Palmas de Gran Canaria
2024-11-20
Active, closed
GlaxoSmithKline
Phase 2
283
Barcelona, León, Madrid, Salamanca, Santander, Valencia
2024-11-11
Active, closed
Abbott Medical - VERITAS Study
NCT06707688Atrial Fibrillation (AF), Stoke
Abbott Medical Devices
Not applicable
458
Barcelona, Madrid, Salamanca
2024-11-07
Recruiting
Snipe Medical
Not applicable
15
Salamanca
2024-11-01
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Málaga, Salamanca
2024-10-29
Recruiting
Clinica Universidad de Navarra, Universidad de Navarra
Observational
39
Madrid, Salamanca
2024-10-21
Active, closed
Merck Sharp & Dohme LLC
Phase 2
66
L'Hospitalet Del Llobregat, Salamanca, Madrid
2024-10-14
Active, closed
Incyte Corporation
Phase 2
130
Barcelona, El Palmar, Granada, Granvia de L'hospitalet 199-203, Madrid, Málaga, Salamanca, Santander
2024-10-11
Recruiting
Fundación para la investigación biomética Hospital Infantil Universitario Niño Jesús
Not applicable
42
A Coruña, Almería, Seville, Palma, Salamanca, Barcelona, Donostia / San Sebastian, Madrid
2024-10-01
Recruiting
Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma
NCT06574126High Risk Smoldering Multiple Myeloma
PETHEMA Foundation
Phase 2
20
Salamanca
2024-09-30
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Majadahonda, Málaga, Lleida, Madrid, Salamanca, Seville, Valladolid, Zaragoza
2024-09-26
Recruiting
Fundación Sociedad Española de Oncologia Médica
Observational
540
Santander, Ciudad Real, Cuenca, Alicante, Arganda, Fuencarral-El Pardo, Fuenlabrada, Salamanca
2024-09-12
Active, closed
GCP-Service International West GmbH
Phase 2
41
Barcelona, León, Madrid, Pamplona, Salamanca, Valencia
2024-09-10
Recruiting
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
NCT06393738Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
DrugGlofitamab
Arvinas Inc.
Phase 1
329
El Palmar, Pamplona, Barcelona, Madrid, Salamanca
2024-09-05
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Salamanca, Valencia
2024-09-04
Recruiting
ReAlta Life Sciences, Inc.
Phase 2
66
Seville, Madrid, Salamanca
2024-08-31
Recruiting
Janssen Research & Development, LLC
Phase 2
210
Badalona, Barcelona, El Palmar, Jerez de la Frontera, Madrid, Pozuelo de Alarcón, Salamanca
2024-08-26
Active, closed
Kite, A Gilead Company
Phase 3
452
Badalona, Barcelona, El Palmar, Madrid, Pamplona, Salamanca, Santander, Seville
2024-08-23
Active, closed
Janssen Research & Development, LLC
Phase 2
43
Madrid, Salamanca, Santander
2024-08-20
By invitation
EEG and NIRS in Preterm Infants
NCT05410340Premature Birth
University of Salamanca
Not applicable
80
Salamanca
2024-08-03
Recruiting
PulseSelect™ PFA Global Registry
NCT06393920Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
1,950
Córdoba, Málaga, Salamanca
2024-07-23
Active, closed
OncoVerity, Inc.
Phase 2
140
Barcelona, Pamplona, Salamanca
2024-07-22
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Badalona, L'Hospitalet de Llobregat, Santander, Barcelona, Madrid, Marbella, Salamanca
2024-07-16
Active, closed
Celldex Therapeutics
Phase 3
963
Sabadell, Alicante, Barcelona, Córdoba, Madrid, Salamanca, Villarreal de Huerva
2024-07-11
Active, closed
AstraZeneca
Phase 3
339
Barcelona, Castellon, Granada, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda, Salamanca
2024-06-29
Active, closed
Byondis B.V.
Phase 1
16
Badalona, Barcelona, Cáceres, Salamanca, Valencia
2024-06-25
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
Huelva, Bilbao, Las Palmas de Gran Canaria, Salamanca, Barcelona, Cataluna, Majadahonda, Islas Baleares
2024-06-25
Active, closed
Ivy Brain Tumor Center
Phase 3
450
Barcelona, Córdoba, Girona, Madrid, Pamplona, Salamanca, Seville
2024-06-19
Active, closed
The Lymphoma Academic Research Organisation
Phase 3
790
Albacete, Barcelona, Las Palmas de Gran Canaria, Lleida, Madrid, Marbella, Oviedo, Salamanca
2024-06-07
Active, closed
Janssen Research & Development, LLC
Phase 1
108
Barcelona, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca, Santander
2024-06-07
Recruiting
Kartos Therapeutics, Inc.
Phase 3
600
Badalona, Barcelona, Cáceres, Las Palmas de Gran Canaria, Madrid, Málaga, Salamanca, Valencia
2024-06-03
Active, closed
Highlight Therapeutics
Phase 2
50
Barcelona, Bilbao, Madrid, Salamanca, Valencia
2024-05-27
Recruiting
Société des Produits Nestlé (SPN)
Not applicable
380
Alicante, Barcelona, Madrid, Salamanca, Sant Cugat del Vallès, Seville, Valencia
2024-05-24
Active, closed
Syndax Pharmaceuticals
Phase 1
96
Santander, Barcelona, Cáceres, Granada, Madrid, Salamanca, Seville, Valencia
2024-05-21
Active, closed
International Extranodal Lymphoma Study Group (IELSG)
Phase 3
122
Barcelona, Bilbao, El Palmar, Madrid, Pamplona, Salamanca, San Sebastián, Valencia
2024-05-21
Active, closed
AbbVie
Phase 3
421
Badalona, Ourense, León, Madrid, Salamanca, Valencia
2024-05-19
Recruiting
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Phase 2
51
Zaragoza, Barcelona, L'Hospitalet de Llobregat, Bilbao, Salamanca, Valladolid, Terrassa, Santiago de Compostela
2024-05-16
Recruiting
Karyopharm Therapeutics Inc
Phase 2
58
Badalona, El Palmar, Oviedo, Cáceres, Girona, Las Palmas de Gran Canaria, Salamanca, Valencia
2024-04-22
Recruiting
AstraZeneca
Phase 3
675
Alicante, Barcelona, Jerez de la Frontera, Reus, Salamanca
2024-04-11
Active, closed
Novo Nordisk A/S
Phase 3
673
Castilleja de la Cuesta, Salamanca, Majadahonda, Madrid, Sanlúcar de Barrameda, Santiago de Compostela, Seville, Valencia
2024-04-01
Recruiting
Instituto de Investigación Biomédica de Salamanca
Phase 1/2
27
Barcelona, L'Hospitalet de Llobregat, Madrid, El Palmar, Pamplona, Salamanca, Seville
2024-03-11
Active, closed
Janssen Research & Development, LLC
Phase 3
731
Alcorcón, Badalona, Barcelona, Manises, Salamanca, Santiago de Compostela, Seville, Villajoyosa
2024-03-09
Recruiting
Novartis Pharmaceuticals
Phase 2
502
Cáceres, Córdoba, Madrid, Salamanca, Valencia
2024-03-07
Active, closed
Genmab
Phase 3
1,095
Badalona, L'Hospitalet de Llobregat, Santander, Pamplona, Barcelona, Cáceres, Madrid, Salamanca
2024-02-05
Recruiting
Comparison of Allegra vs Sapien Transcatheter Aortic Valves in Valve-In-Valve Indication
NCT06049654Aortic Valve Stenosis, Structural Valve Deterioration
Fundación EPIC
Not applicable
104
L'Hospitalet de Llobregat, Madrid, Majadahonda, Salamanca, Valencia
2024-02-01
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
187
Pamplona, Salamanca
2024-01-23
Active, closed
Sanofi
Phase 3
260
Santander, Barcelona, Madrid, Málaga, Salamanca, Seville, Valencia
2024-01-23
Not yet open
Fundacion Clinic per a la Recerca Biomédica
Early Phase 1
40
Santiago de Compostela, Barcelona, Madrid, Murcia, Oviedo, Palma de Mallorca, Salamanca
2024-01-15
Recruiting
Instituto de Investigación Biomédica de Salamanca
Observational
100
Salamanca
2024-01-01
Recruiting
Instituto de Investigación Biomédica de Salamanca
Observational
40
Salamanca
2024-01-01
Recruiting
EMG Analysis in ABI: Motor Imagery and Action
NCT06230718Stroke, Quality of Life, Mirror Movement
University of Salamanca
Not applicable
28
Salamanca
2024-01-01
Recruiting
Instituto de Investigación Biomédica de Salamanca
Observational
300
Badalona, Barcelona, Pamplona, Salamanca
2024-01-01
Active, closed
Instituto de Investigación Biomédica de Salamanca
Observational
300
Salamanca
2024-01-01
Recruiting
Bristol-Myers Squibb
Phase 1/2
460
Málaga, Barcelona, Madrid, Pamplona, Salamanca
2023-12-29
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Barcelona, Madrid, Salamanca, Seville, Valencia
2023-12-29
Active, closed
Regeneron Pharmaceuticals
Phase 1/2
148
Badalona, Pozuelo de Alarcón, Pamplona, Oviedo, Alicante, Barcelona, Madrid, Salamanca
2023-12-19
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
L'Hospitalet Del Llobregat, Barcelona, Pozuelo de Alarcón, Majadahonda, San Cristóbal de La Laguna, Salamanca
2023-12-13
Active, closed
Janssen Research & Development, LLC
Phase 1
70
Barcelona, Madrid, Pamplona, Salamanca
2023-12-06
Recruiting
AstraZeneca
Phase 1/2
226
Badalona, Madrid, Pamplona, Salamanca
2023-12-05
Recruiting
Effect of Cryotherapy in the Prevention of Madarosis Produced by Chemotherapy in Breast Cancer Patients
NCT06955702Breast Neoplasms, Alopecia, Madarosis, Eyebrow Diseases
University of Salamanca
Not applicable
120
Santander, Salamanca
2023-11-15
Active, closed
GlaxoSmithKline
Phase 2
316
Barcelona, Jaén, Madrid, Pozuelo de AlarcOn Madr, Salamanca, Santander, Valencia, Zaragoza
2023-11-14
Recruiting
University of Salamanca
Not applicable
200
Salamanca
2023-11-02
Recruiting
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
NCT05862012Relapsed/Refractory Multiple Myeloma
Ichnos Sciences SA
Phase 1
200
Salamanca, Badalona, Barcelona, Madrid, Pamplona
2023-11-01
Recruiting
MaaT Pharma
Phase 2
387
Barcelona, Granada, Madrid, Majadahonda, Murcia, Pamplona, Salamanca, Santander
2023-10-31
Active, closed
Bristol-Myers Squibb
Phase 3
402
Barcelona, L'Hospitalet de Llobregat, Valencia, Granada, Madrid, Oviedo, Salamanca, Seville
2023-10-24
Active, closed
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 2
114
Barcelona, Madrid, Salamanca, Seville, Terrassa
2023-10-23
Active, closed
Celgene
Phase 3
79
Badalona, L'Hospitalet Del Llobregat, Barcelona, Pamplona, Madrid, Salamanca, Valencia
2023-10-16
Active, closed
Stichting European Myeloma Network
Phase 3
759
Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santiago de Compostela, Seville, Valencia
2023-10-10
Active, closed
Bristol-Myers Squibb
Phase 3
106
L'Hospitalet de Llobregat, Barcelona, Granada, Madrid, Ourense, Salamanca, Valencia
2023-10-05
Active, closed
Acrotech Biopharma Inc.
Phase 3
504
Bilbao, Moncloa-Aravaca, Pamplona, Barcelona, Madrid, Salamanca, Valencia
2023-10-04
Active, closed
Novartis Pharmaceuticals
Phase 3
109
Santiago Compostela, L'Hospitalet de Llobregat, Santander, El Palmar, Barcelona, Córdoba, Madrid, Salamanca
2023-10-02
Recruiting
Novartis Pharmaceuticals
Phase 3
106
Pamplona, Almería, Barcelona, Madrid, Salamanca
2023-10-02
Active, closed
PETHEMA Foundation
Phase 2
30
Badalona, Barcelona, Madrid, Murcia, Pamplona, Salamanca, Santander, Santiago de Compostela
2023-09-21
Recruiting
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
NCT05365659B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
Iksuda Therapeutics Ltd.
Phase 1
140
Badalona, Madrid, Salamanca
2023-09-05
Active, closed
Fundació d'investigació Sanitària de les Illes Balears
Phase 3
110
Granada, Palma de Mallorca, Barcelona, Madrid, Murcia, Salamanca, Pontevedra, Zaragoza
2023-09-01
Active, closed
Cytokinetics
Phase 3
500
A Coruña, Barcelona, Madrid, Málaga, Murcia, Palma de Mallorca, Salamanca, Seville
2023-08-31
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Majadahonda, Málaga, Barcelona, Lleida, Madrid, Salamanca, Seville, Valladolid
2023-07-11
Active, closed
AbbVie
Phase 1
135
Majadahonda, Barcelona, Madrid, Salamanca
2023-06-09
Recruiting
Development and Validation of a Blood Test for Early Diagnosis of Colorectal Cancer
NCT06889883Colorectal Carcinoma, Advanced Adenomas (AA)
ADVANCED MARKER DISCOVERY S.L.
Observational
510
Zaragoza, Bilbao, Donostia / San Sebastian, Santander, Salamanca, Barcelona, Madrid, Oviedo
2023-06-06
Recruiting
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
NCT05908409Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double Hit Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified
DrugIDP-121
IDP Discovery Pharma S.L.
Phase 1/2
37
Santander, Salamanca, Barcelona, Madrid, Murcia, Seville, Valencia, Zaragoza
2023-06-05
Active, closed
Gilead Sciences
Phase 3
654
Barcelona, Bilbao, Córdoba, Elche, Jaén, Madrid, Salamanca, Santiago de Compostela
2023-05-08
Recruiting
Usefulness of PET-CT for Invasive Fungal Infection
NCT05688592Invasive Fungal Infections
Puerta de Hierro University Hospital
Observational
224
Majadahonda, Barcelona, Granada, Madrid, Málaga, Murcia, Oviedo, Salamanca
2023-04-27
Active, closed
Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients
NCT05705973Cardiovascular Disease, Coronary Artery Occlusion, Ischemic Heart Disease
Terumo Europe N.V.
Observational
3,000
Barcelona, Huelva, León, Salamanca, Seville
2023-04-25
Recruiting
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Phase 3
1,000
Barcelona, Madrid, Salamanca, Valencia
2023-04-18
Recruiting
Early Onset Colorectal Cancer Detection
NCT06342401Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Stage I
City of Hope Medical Center
Observational
400
Barcelona, Madrid, Salamanca, San Cristóbal de La Laguna
2023-04-15
Recruiting
Study of SGR-1505 in Mature B-Cell Neoplasms
NCT05544019Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia
Schrödinger, Inc.
Phase 1
98
Barcelona, Madrid, Pamplona, Salamanca
2023-04-10
By invitation
Sanofi
Phase 2
70
Seville, Badalona, Santander, Salamanca, Pamplona, Madrid
2023-04-05
Recruiting
AbbVie
Phase 1
250
Santander, Majadahonda, Salamanca
2023-03-21
Recruiting
K36 Therapeutics, Inc.
Phase 1
165
Pamplona, Barcelona, Madrid, Salamanca
2023-02-22
Active, closed
Kite, A Gilead Company
Phase 3
300
Barcelona, Madrid, Salamanca, Santander, Seville, Valencia
2023-02-10
Active, closed
Novartis Pharmaceuticals
Phase 3
152
Santiago Compostela, Salamanca
2023-02-02
Active, closed
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Observational
88
Santander, Córdoba, Granada, Madrid, Málaga, Salamanca, Seville, Valencia
2023-01-23
Recruiting
Jazz Pharmaceuticals
Phase 3
510
Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Valencia
2023-01-23
Recruiting
Alleviant ALLAY-HF Study
NCT05685303Heart Failure
Alleviant Medical, Inc.
Not applicable
700
Barcelona, Cadiz, Madrid, Salamanca, Valencia
2023-01-10
Active, closed
AriBio Co., Ltd.
Phase 3
1,535
Barcelona, Huelva, Madrid, Pamplona, Salamanca, San Sebastián, Seville, Valencia
2022-12-23
Active, closed
PETHEMA Foundation
Phase 2
140
Madrid, Palma de Mallorca, Pamplona, Salamanca, San Cristóbal de La Laguna, Santander, Seville, Valencia
2022-12-15
Active, closed
Bristol-Myers Squibb
Phase 2/3
230
Valencia, Granada, Madrid, Ourense, Oviedo, Salamanca
2022-12-14
Active, closed
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase 3
129
Barcelona, Burgos, A Coruña, Granada, Madrid, Murcia, Málaga, Salamanca
2022-12-02
Recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
NCT05652335Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
DrugRamantamig
Janssen Research & Development, LLC
Phase 1
180
Badalona, Barcelona, Madrid, Pamplona, Salamanca
2022-11-22
Active, closed
Agios Pharmaceuticals, Inc.
Phase 2
87
Córdoba, Madrid, Salamanca, Seville
2022-11-07
Active, closed
Hoffmann-La Roche
Phase 1
121
L'Hospitalet de Llobregat, Valencia, Barcelona, Madrid, Salamanca
2022-10-26
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Badalona, Barcelona, Granada, Jerez de la Frontera, Madrid, Palma de Mallorca, Pozuelo de Alarcón, Salamanca
2022-10-25
Active, closed
Almirall, S.A.
Phase 4
447
Barcelona, Granada, Madrid, Salamanca, Seville, Valencia, Zaragoza
2022-10-24
Active, closed
Kite, A Gilead Company
Phase 3
231
Barcelona, Madrid, Salamanca, Seville, Valencia
2022-09-22
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
410
Barcelona, Madrid, Salamanca, Seville, Valladolid, Zamora, Zaragoza
2022-08-23
Recruiting
Regeneron Pharmaceuticals
Phase 1
317
Santiago de Compostela, Badalona, Santander, Pozuelo de Alarcón, Pamplona, Barcelona, Madrid, Salamanca
2022-08-17
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsNemtabrutinib·Zilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 2
189
L'Hospitalet Del Llobregat, Barcelona, Madrid, Pamplona, Salamanca
2022-07-21
Active, closed
Incyte Corporation
Phase 1/2
53
Palma de Mallorca, Girona, L'Hospitalet de Llobregat, Madrid, Salamanca, Seville, Valencia
2022-07-19
Recruiting
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
NCT05475925LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma
DrugDibotatug
Dren Bio
Phase 1/2
200
Barcelona, Salamanca
2022-07-13
Active, closed
Novartis Pharmaceuticals
Phase 3
610
A Coruña, Barcelona, Córdoba, Madrid, Salamanca, Valencia
2022-07-08
Recruiting
PMCF Study on the Safety, Performance and Clinical Benefits Data of the Anatomical Shoulder 2.0 Fracture System
NCT05351112Proximal Humerus Fracture, Posttraumatic Arthrosis After Humeral Head Fracture, Posttraumatic Necrosis of the Humeral Head
Zimmer Biomet
Observational
78
Salamanca
2022-07-07
Active, closed
Sanofi
Phase 3
531
Murcia, Badalona, Santander, Pamplona, Madrid, Salamanca
2022-06-23
Active, closed
ADC Therapeutics S.A.
Phase 1
154
Barcelona, Madrid, Salamanca, Valencia
2022-06-17
Recruiting
Priothera SAS
Phase 3
366
Barcelona, Granada, Las Palmas de Gran Canaria, Madrid, Salamanca, Valencia
2022-06-16
Active, closed
Genmab
Phase 2
264
Badalona, L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Seville, Valencia
2022-06-14
Recruiting
Neck Evolution With Ovation in Spain
NCT05823519Abdominal Aortic Aneurysm
DGM Vascular
Observational
120
Palma de Mallorca, Girona, Barakaldo, Burgos, Salamanca, Toledo, Gijón, Barcelona
2022-06-01
Active, closed
Janssen Research & Development, LLC
Phase 1
74
Badalona, Madrid, Pamplona, Salamanca
2022-05-25
Active, closed
SOLTI Breast Cancer Research Group
Phase 2
1,100
Palma de Mallorca, Badalona, L'Hospitalet de Llobregat, Barcelona, Granada, León, Madrid, Salamanca
2022-05-03
Active, closed
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755Moderate Aortic Valve Stenosis
Medtronic Cardiovascular
Not applicable
650
Barcelona, Madrid, Salamanca, Valladolid
2022-04-27
Recruiting
Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With TricValve®
NCT05114850Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Insufficiency, Heart Failure
P+F Products + Features GmbH
Observational
450
Galdakao, Málaga, Barcelona, Córdoba, Lugo, Madrid, Oviedo, Salamanca
2022-04-20
Active, closed
European Myeloma Network B.V.
Phase 3
117
Barcelona, Gijón, Girona, Madrid, Murcia, Pamplona, Salamanca, Santander
2022-04-19
Active, closed
Pfizer
Phase 3
854
Santiago de Compostela, Barcelona, L'Hospitalet Del Llobregat, Terrassa, Badalona, Salamanca, Pozuelo de Alarcón, Madrid
2022-03-25
Active, closed
Hoffmann-La Roche
Phase 2
46
Barcelona, Madrid, Salamanca
2022-03-22
Active, closed
Parenteral Antiplatelet Agents in Real-world Spanish PCI Patients
NCT05193019Ischemic Heart Disease, Acute Coronary Syndrome
Fundación EPIC
Observational
717
L'Hospitalet de Llobregat, Barakaldo, Galdakao, Gijón, León, Madrid, Pamplona, Salamanca
2022-03-14
Recruiting
Janssen Research & Development, LLC
Phase 4
295
Pamplona, Salamanca
2022-03-09
Active, closed
Janssen Research & Development, LLC
Phase 2
151
Badalona, Barcelona, Madrid, Pamplona, Salamanca
2022-03-01
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax
Sumitomo Pharma America, Inc.
Phase 1/2
606
Albacete, Barcelona, Cáceres, Las Palmas, Madrid, Oviedo, Salamanca, Santander
2022-02-28
Active, closed
177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
NCT05204927Metastasis From Malignant Tumor of Prostate
DrugEnzalutamide
Curium US LLC
Phase 3
439
Madrid, Málaga, Salamanca
2022-02-14
Recruiting
REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs
NCT05223413Anthracycline-induced Cardiac Toxicity, Lymphoma
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Not applicable
608
Alcalá de Henares, Barcelona, Granada, Madrid, Salamanca, Seville, Valladolid
2022-01-18
Recruiting
Takeda
Phase 2
135
Badalona, Barcelona, Madrid, Salamanca, Valencia, Zaragoza
2021-12-16
By invitation
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
NCT05041309Solid and Hematological Malignancies, Autoimmune Diseases
DrugsKITE-197·SPRX002·KITE-753·Tecartus
Kite, A Gilead Company
Observational
1,500
Barcelona, Salamanca
2021-12-15
Active, closed
Amgen
Phase 3
303
Córdoba, Seville, Santander, Salamanca, Badalona, Barcelona, L'Hospitalet de Llobregat, Valencia
2021-11-02
Active, closed
GWT-TUD GmbH
Phase 3
70
Badalona, Barcelona, Madrid, Oviedo, Salamanca, Valencia
2021-10-27
Active, closed
Janssen Research & Development, LLC
Phase 3
587
Barcelona, Gijón, Las Palmas de Gran Canaria, Madrid, Palma, Pamplona, Pozuelo de Alarcón, Salamanca
2021-10-14
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Pamplona, Barcelona, Salamanca
2021-09-20
Active, closed
Celgene
Phase 1
224
Barcelona, Málaga, Salamanca
2021-09-15
Recruiting
A Registry Study on HIV-related Lymphoma
NCT05231135AIDS Related Lymphoma, HIV Related Lymphoma
Rotkreuzklinikum München gGmbH
Observational
300
Barcelona, Salamanca
2021-08-25
Active, closed
Janssen Research & Development, LLC
Phase 3
743
Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Pamplona, Salamanca, Santander, Seville
2021-08-19
Recruiting
Miltenyi Biomedicine GmbH
Phase 2
213
Barcelona, Madrid, Murcia, Pamplona, Salamanca
2021-08-18
Active, closed
Enterome
Phase 1/2
80
Barcelona, Madrid, Pamplona, Salamanca
2021-07-05
Active, closed
AstraZeneca
Phase 3
506
Barcelona, Bilbao (Vizcaya), Granada, Madrid, Salamanca, Santander, Santiago de Compostela-Coruña, Seville
2021-06-22
Active, closed
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Phase 3
124
Barcelona, Madrid, Málaga, Murcia, Pamplona, Salamanca
2021-05-26
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
DrugsPosaconazole·Sonrotoclax·Azacitidine
BeOne Medicines
Phase 1/2
260
Barcelona, Salamanca, Seville, Valencia
2021-05-24
Recruiting
Immune Checkpoint Inhibitors Nephrotoxicity
NCT04902846Kidney Injury, Antineoplastics Toxicity
R. Laura Vicente Vicente
Observational
220
Salamanca, Valladolid
2021-05-19
Recruiting
Janssen Research & Development, LLC
Phase 1/2
420
Barcelona, Madrid, Pamplona, Salamanca, Seville, Valencia
2021-05-19
Active, closed
Incyte Corporation
Phase 3
899
Badalona, Barcelona, Girona, Jerez de la Frontera, Lugo, Madrid, Pamplona, Salamanca
2021-05-11
Recruiting
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
NCT04614103Metastatic Non Small Cell Lung Cancer
DrugLifileucel
Iovance Biotherapeutics, Inc.
Phase 2
170
A Coruña, Barcelona, Córdoba, Madrid, Málaga, Pamplona, Salamanca, Seville
2021-05-07
By invitation
Cytokinetics
Phase 2/3
900
A Coruña, Barcelona, Madrid, Málaga, Palma, Pontevedra, Salamanca, Seville
2021-05-06
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Oviedo, Badalona, Barcelona, Cáceres, Las Palmas de Gran Canaria, Madrid, Murcia, Salamanca
2021-04-09
Active, closed
PETHEMA Foundation
Phase 2
50
Palma de Mallorca, Santander, Salamanca, Santiago de Compostela, Madrid, Gijón, Valencia, Las Palmas de Gran Canaria
2021-04-07
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
L'Hospitalet de Llobregat, Salamanca, A Coruña, Alicante, Barcelona, Madrid
2021-04-05
Active, closed
Bristol-Myers Squibb
Phase 1/2
216
Badalona, Santander, Madrid, Salamanca, Valencia
2021-03-22
Recruiting
Syndax Pharmaceuticals
Phase 2
296
Seville, Barcelona, Donostia / San Sebastian, Granada, Madrid, Majadahonda, Salamanca, Santander
2021-03-04
Active, closed
German CLL Study Group
Phase 3
897
Badalona, Barcelona, Madrid, Málaga, Oviedo, Salamanca, Santander, Seville
2021-03-01
Active, closed
Celgene
Phase 3
313
Barcelona, Granada, Las Palmas de Gran Canaria, Madrid, Palma de Mallorca, Salamanca, Santiago de Compostela, Seville
2021-02-25
Active, closed
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
NCT04279847Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm
DrugRuxolitinib
Incyte Corporation
Phase 1
140
Badalona, Las Palmas de Gran Canaria, Madrid, Murcia, Salamanca
2021-02-23
Active, closed
Taiho Oncology, Inc.
Phase 1/2
101
Oviedo, L'Hospitalet de Llobregat, Pamplona, Madrid, Salamanca, Valencia
2021-02-09
Active, closed
Sellas Life Sciences Group
Phase 3
127
Cáceres, Córdoba, Madrid, Oviedo, Pamplona, Salamanca, Seville, Valencia
2021-02-08
Recruiting
Janssen Research & Development, LLC
Phase 2
510
Badalona, Barcelona, Madrid, Murcia, Pamplona, Pozuelo de Alarcón, Salamanca, Santander
2021-02-01
Active, closed
Genmab
Phase 3
483
Badalona, Barcelona, Cadiz, Cáceres, Córdoba, Lleida, Madrid, Salamanca
2021-01-13
Active, closed
Amgen
Phase 1/2
181
Seville, Santander, Salamanca, Badalona, Barcelona, Esplugues de Llobregat, L'Hospitalet de Llobregat, Pamplona
2021-01-04
Active, closed
Janssen Research & Development, LLC
Phase 1/2
228
Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Salamanca, Santander
2020-12-15
Active, closed
PARADIGM: Amplatzer Valvular Plug for PVL Closure
NCT04489823Paravalvular Aortic Regurgitation
Abbott Medical Devices
Not applicable
200
Madrid, Salamanca
2020-12-01
Active, closed
Eclipse Medical Ltd.
Not applicable
200
Valladolid, Madrid, Salamanca, Barcelona
2020-11-17
Active, closed
Genmab
Phase 1/2
543
Barcelona, Madrid, Salamanca
2020-11-03
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
281
Barcelona, Gijón, Granada, Madrid, Majadahonda, Pamplona, Salamanca, Seville
2020-11-03
Active, closed
CHAMPION-AF Clinical Trial
NCT04394546Atrial Fibrillation, Stroke, Bleeding
DrugsNon-Vitamin K Anticoagulant·NOAC
Boston Scientific Corporation
Not applicable
3,000
Vigo, León, Salamanca
2020-10-15
Active, closed
Hoffmann-La Roche
Phase 3
210
Bilbao, Badalona, Las Palmas de Gran Canaria, Barcelona, Cáceres, Madrid, Salamanca
2020-10-08
Recruiting
QualiMed Innovative Medizinprodukte GmbH
Observational
198
Salamanca
2020-10-03
Active, closed
Hoffmann-La Roche
Phase 3
190
Badalona, Santiago de Compostela, Asturias, Bilbao, Barcelona, Madrid, Málaga, Salamanca
2020-09-30
Active, closed
European Myeloma Network B.V.
Phase 3
302
Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander
2020-09-25
Active, closed
Janssen Research & Development, LLC
Phase 2
194
Badalona, Barcelona, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca, Santander
2020-09-17
Active, closed
AbbVie
Phase 3
531
Badalona, Córdoba, Pozuelo de Alarcón, Barcelona, Madrid, Salamanca, Seville, Valencia
2020-09-10
Recruiting
Takeda
Phase 2
210
Barcelona, Salamanca, Seville, Valencia
2020-08-19
Active, closed
Prognosis Impact of NSVTs After an AMI (TeVeO Study).
NCT04765943Death, Sudden, Ventricular Tachycardia, Implantable Defibrillator User, Myocardial Infarction
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Observational
224
Salamanca
2020-08-15
Active, closed
Incyte Corporation
Phase 2
112
Alicante, Badalona, Barcelona, Boadilla del Monte, L'Hospitalet de Llobregat, Madrid, Pozuelo de Alarcón, Salamanca
2020-08-03
Active, closed
Medtronic
Observational
2,200
A Coruña, Granda, Madrid, Salamanca, Santa Cruz de Tenerife, Santiago, Valladolid
2020-08-01
Active, closed
Medtronic
Observational
2,200
A Coruña, Granada, Madrid, Salamanca, Santa Cruz de Tenerife, Santiago, Valladolid
2020-08-01
Active, closed
Celgene
Phase 2
276
Madrid, Salamanca, Seville
2020-07-14
Active, closed
Amplatzer Amulet LAAO vs. NOAC
NCT04226547Atrial Fibrillation, Stroke, Bleeding
DrugNOAC
Abbott Medical Devices
Not applicable
2,650
Madrid, Barcelona, Salamanca
2020-07-07
Active, closed
Actelion
Phase 3
935
Barcelona, Madrid, Málaga, Salamanca
2020-06-30
Active, closed
Sanofi
Phase 3
337
Barcelona, Pamplona, Valencia, Madrid, Salamanca, Zaragoza
2020-06-16
Active, closed
Janssen Research & Development, LLC
Phase 3
419
Badalona, Barcelona, Madrid, Pamplona, Salamanca, Seville
2020-06-12
Active, closed
Epizyme, Inc.
Phase 3
599
Barcelona, Marbella, El Palmar, Madrid, Pamplona, Salamanca, Seville
2020-06-11
Active, closed
GlaxoSmithKline
Phase 3
494
Barcelona, Cáceres, Gijón, L'Hospitalet de Llobrega, Murcia, PamplonaNavarra, Salamanca
2020-05-07
Active, closed
BeOne Medicines
Phase 1
437
Barcelona, Madrid, Salamanca, Santander
2020-03-24
Active, closed
Janssen Research & Development, LLC
Phase 1
290
Barcelona, Madrid, Pamplona, Salamanca
2020-02-21
Active, closed
BeOne Medicines
Phase 3
955
Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Salamanca, Toledo
2020-01-16
Recruiting
Sumitomo Pharma America, Inc.
Phase 1/2
240
Barcelona, Salamanca
2019-12-16
Active, closed
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia
NCT04232241Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes
Universitätsklinikum Hamburg-Eppendorf
Phase 2
167
Badalona, Barcelona, Madrid, Salamanca, Seville, Valencia
2019-11-14
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Palma, Barcelona, Pozuelo de Alarcón, Madrid, Salamanca, Valencia
2019-11-13
Active, closed
Janssen Research & Development, LLC
Phase 2
208
Pamplona, Salamanca
2019-11-07
Active, closed
Nouscom SRL
Phase 1/2
115
A Coruña, Barcelona, Córdoba, Granada, Madrid, Pamplona, Salamanca, Santander
2019-10-21
Active, closed
SyncAV Post-Market Trial
NCT04100148Congestive Heart Failure
Abbott Medical Devices
Not applicable
1,686
Badajoz, Barcelona, Madrid, Málaga, Salamanca
2019-10-03
Active, closed
Celgene
Phase 1/2
424
Badalona, Madrid, Málaga, Pamplona, Salamanca, Santander, Valencia
2019-09-30
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
DrugLuspatercept
Celgene
Phase 3
665
Barakaldo, Barcelona, Madrid, Oviedo, Salamanca, Seville, Valencia
2019-08-12
Active, closed
Hoffmann-La Roche
Phase 3
1,013
Pozuelo de Alarcón, El Palmar, Vigo, Barcelona, Madrid, Salamanca, Seville, Valencia
2019-08-12
Recruiting
Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)
NCT03711110Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Elderly, Antineoplastic Agents, Cardiotoxicity
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Not applicable
514
Santiago de Compostela, Galdakao, Barcelona, Córdoba, Madrid, Málaga, Salamanca, Seville
2019-08-02
Active, closed
OncoVerity, Inc.
Phase 2
103
Pozuelo de Alarcón, Barcelona, Córdoba, Madrid, Palma, Salamanca, Valencia
2019-07-29
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
DrugIbrutinib
Novartis Pharmaceuticals
Phase 1/2
218
Badalona, L'Hospitalet de Llobregat, Barcelona, Córdoba, Madrid, Salamanca, Seville, Valencia
2019-06-26
Recruiting
European Organisation for Research and Treatment of Cancer - EORTC
Observational
2,000
Badalona, Barcelona, Cartagena, Córdoba, Madrid, Pamplona, Salamanca, Terrassa
2019-06-24
Active, closed
Regeneron Pharmaceuticals
Phase 3
415
Barcelona, Alcorcón, Torrejón de Ardoz, Badalona, Madrid, Majadahonda, Salamanca, Seville
2019-06-04
Active, closed
Celgene
Phase 1/2
438
Badalona (Barcelona), Barcelona, Madrid, Málaga, Salamanca
2019-05-20
By invitation
University of Edinburgh
Observational
287
Barcelona, Salamanca
2019-04-05
Active, closed
Eisai Inc.
Phase 3
1,906
Sant Cugat del Vallès, Getxo, Donostia / San Sebastian, Barcelona, Córdoba, Madrid, Salamanca, Seville
2019-03-27
Recruiting
Abbott Medical Devices
Observational
2,000
Salamanca, Majadahonda, Valencia
2019-03-13
Active, closed
Acerta Pharma BV
Phase 3
984
Badalona, Barcelona, Madrid, Majadahonda, Salamanca, Santander, Valencia
2019-02-25
Active, closed
Follow-up in Gynecological Cancer Survivors
NCT03515993Gynecologic Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Observational
1,100
Madrid, Pamplona, Salamanca
2019-02-21
Active, closed
NVT GmbH
Observational
346
Madrid, Málaga, Salamanca, Vigo
2019-02-20
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
387
Barcelona, Pamplona, Madrid, Salamanca
2019-01-23
Active, closed
Kartos Therapeutics, Inc.
Phase 2
20
Las Palmas de Gran Canaria, Málaga, Salamanca
2019-01-15
Active, closed
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
DrugsPonatinib·Imatinib·Cytarabine·Methotrexate
Takeda
Phase 3
245
Badalona, Barcelona, Salamanca, Valencia
2018-10-04
Recruiting
Celgene
Phase 2/3
1,541
Barcelona, Córdoba, Esplugues de Llobregat, Madrid, Málaga, Pamplona, Salamanca, Santander
2018-07-19
Active, closed
Janssen Research & Development, LLC
Phase 3
211
Barcelona, Madrid, Pamplona, Salamanca, Seville
2018-04-17
Active, closed
AbbVie
Phase 3
1,336
Ferrol, L'Hospitalet de Llobregat, Sabadell, Majadahonda, Bilbao, Barcelona, Madrid, Salamanca
2018-04-09
Active, closed
Janssen Research & Development, LLC
Phase 1
279
Badalona, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca
2017-12-16
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
61
Badalona, Madrid, Málaga, Salamanca, Valencia
2017-12-01
Active, closed
Medtronic
Observational
1,092
A Coruña, Granada, Madrid, Salamanca, Santa Cruz de Tenerife, Santiago de Compostela, Valladolid
2017-08-21
Active, closed
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
NCT02952508Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugCLR 131
Cellectar Biosciences, Inc.
Phase 2
120
Barcelona, Madrid, Salamanca, Zaragoza
2017-07-26
Active, closed
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugPacritinib
Swedish Orphan Biovitrum
Phase 3
407
Barcelona, Madrid, Murcia, Salamanca, Seville, Valencia
2017-06-26
Active, closed
Alliance Foundation Trials, LLC.
Phase 3
518
Barcelona, Madrid, Málaga, Murcia, Navarro, Salamanca, Santiago, Seville
2017-06-21
Active, closed
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
NCT03229200Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease
DrugIbrutinib
Pharmacyclics Switzerland GmbH
Phase 4
297
Badalona, Majadahonda, Barcelona, Madrid, Salamanca
2017-05-22
Active, closed
Janssen Research & Development, LLC
Phase 1
302
Badalona, Barcelona, Pamplona, Salamanca
2017-05-16
Active, closed
Acerta Pharma BV
Phase 3
310
Badalona, Madrid, Majadahonda, Salamanca, Santander, Valencia
2017-02-02
Active, closed
AbbVie
Phase 3
950
A Coruña, Santiago de Compostela, Santander, Las Palmas de Gran Canaria, Barcelona, Córdoba, Madrid, Salamanca
2017-01-31
Active, closed
Astellas Pharma Global Development, Inc.
Phase 2
900
Barcelona, Girona, Madrid, Pamplona, Salamanca, Santiago de Compostela
2016-12-22
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Esplugues, L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Seville, Valencia
2015-11-02
Active, closed
Phase III Radium 223 mCRPC-PEACE III
NCT02194842Prostate Cancer
DrugsRa223·Enzalutamide
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
446
Barcelona, Madrid, Pamplona, Sabadell, Salamanca
2015-10
Active, closed
PETHEMA Foundation
Phase 2
90
Barcelona, Madrid, Murcia, Oviedo, Pamplona, Plama de Mallorca, Salamanca, Santa Cruz de Tenerife
2015-05
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
DrugsPanobinostat·Jakavi·Ruxolitinib
Novartis Pharmaceuticals
Phase 4
279
Barcelona, Pamplona, Salamanca
2015-03-05
Active, closed
Karyopharm Therapeutics Inc
Phase 2
244
Badalona, Barcelona, Madrid, Palma de Mallorca, Pamplona, Salamanca, Seville
2014-11
Active, closed
Acerta Pharma BV
Phase 2
107
Salamanca
2014-09-11
Active, closed
University of Sydney
Phase 3
802
Badalona, Donostia / San Sebastian, Salamanca
2014-03
Active, closed
UNICANCER
Phase 3
1,173
Badalona, Barcelona, Girona, Madrid, Manresa, Málaga, Sabadell, Salamanca
2013-11-13
Active, closed
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
DrugIbrutinib
Janssen Research & Development, LLC
Phase 3
539
Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Salamanca
2013-09-09
Active, closed
Janssen Scientific Affairs, LLC
Observational
21,190
Alcalá de Henares, Bilbao, Granada, Madrid, Majadahonda, Murcia, Salamanca, Santiago de Compostela
2007-06-21
Active, closed
AstraZeneca
Phase 3
736
A Coruña, Madrid, Málaga, Oviedo, Salamanca, Seville
2005-02-13
Recruiting
Medtronic
Observational
20,000
A Coruña, Barcelona, Córdoba, Girona, Granada, Madrid, Palma de Mallorca, Salamanca
1983-01
Rows per page Showing 1–363 of 363
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 14 November 2026. https://priyalifescience.com/clinical-trials-spain/city/salamanca

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,909 studies in total at the last sync on 13 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 363 of those studies with a site in Salamanca.

How many clinical trials are recruiting in Salamanca?

174 of the 363 studies on this page are recruiting new participants as of the 13 Nov 2026, 03:19 UTC sync. A further 20 have not yet opened recruitment, 162 are active but closed to new participants, and 7 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Salamanca), 363 studies
PhaseStudiesRecruitingShare
Phase 31234833.9%
Phase 2783621.5%
Not applicable462612.7%
Observational452912.4%
Phase 1/229168%
Phase 128127.7%
Phase 4731.9%
Phase 2/3641.7%
Early Phase 1100.3%

Most active sponsors

Lead sponsors with the most studies (Salamanca)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC2910
University of Salamanca2010
AstraZeneca1610
Novartis Pharmaceuticals156
Instituto de Investigación Biomédica de Salamanca1312
Bristol-Myers Squibb95
Celgene93
Merck Sharp & Dohme LLC96
Takeda98
AbbVie72
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.